Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) EBITDA Margin (2020 - 2022)

Elicio Therapeutics filings provide 3 years of EBITDA Margin readings, the most recent being 1117.76% for Q2 2022.

  • On a quarterly basis, EBITDA Margin rose 203112.0% to 1117.76% in Q2 2022 year-over-year; TTM through Mar 2023 was 4468.15%, a 435684.0% decrease, with the full-year FY2022 number at 1225.9%, down 102833.0% from a year prior.
  • EBITDA Margin hit 1117.76% in Q2 2022 for Elicio Therapeutics, down from 869.9% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1308.03% in Q4 2020 to a low of 9876.28% in Q1 2021.
  • Median EBITDA Margin over the past 3 years was 1117.76% (2022), compared with a mean of 2185.24%.
  • Biggest five-year swings in EBITDA Margin: plummeted -124891bps in 2021 and later soared 900638bps in 2022.
  • Elicio Therapeutics' EBITDA Margin stood at 1308.03% in 2020, then crashed by -95bps to 59.12% in 2021, then tumbled by -1991bps to 1117.76% in 2022.
  • The last three reported values for EBITDA Margin were 1117.76% (Q2 2022), 869.9% (Q1 2022), and 59.12% (Q4 2021) per Business Quant data.